Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis
Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis
复制标题
DOI：
10.1016/s0165-5728(99)00149-6
复制
发表时间：
2000-01-03
影响因子：
3.3
通讯作者：
Biegon, A
中科院分区：
文献类型：
--
作者：
Achiron, A;Miron, S;Biegon, A
Dexanabinol（HU-211）是一种合成的非精神性大麻素，其抑制脑和外周血中TNF-α的产生。采用不同剂量、给药方式和给药时间研究了地塞米诺对大鼠实验性自身免疫性脑脊髓炎（EAE）的作用。在疾病发作后（第10天）静脉注射一次5 mg/kg地塞米诺，可显著降低最大EAE评分。增加剂量或治疗持续时间可进一步抑制EAE。在疾病诱导期间的早期阶段给药无效。组织学研究支持临床结果，证明用地塞米诺治疗的动物的脑和脊髓中的炎症反应减少。结果表明，地塞米诺可能为多发性硬化症（MS）急性加重提供一种替代治疗模式。(C)2000 Elsevier Science B. V.保留所有权利。
Dexanabinol (HU-211) is a synthetic non-psychotropic cannabinoid which suppresses TNF-a production in the brain and peripheral blood. The effects of dexanabinol in rat experimental autoimmune encephalomyelitis (EAE) were studied using different doses, modes of administration and time regimes. Dexanabinol, 5 mg/kg i.v. given once after disease onset (day 10), significantly reduced maximal EAE score. Increasing the dose or treatment duration resulted in further suppression of EAE. Drug administration at earlier phases during disease induction was not effective. Histological studies supported the clinical findings demonstrating reduction in the inflammatory response in the brain and spinal cord in animals treated with dexanabinol. The results suggest that dexanabinol may provide an alternative mode of treatment for acute exacerbations of multiple sclerosis (MS). (C) 2000 Elsevier Science B.V. All rights reserved.